James O'Mara runs a small company with a large ambition. As President and CEO of Neurogastrx, a specialty pharmaceutical firm headquartered in Woburn, Massachusetts, he is steering an oral drug candidate called NG101 through the clinic. The pitch is unglamorous and, if it works, enormous: keep patients on the medicines that help them by taking away the nausea that makes so many of them quit.
The context is the GLP-1 boom. Drugs like semaglutide have reshaped how the world treats diabetes and obesity, but their gastrointestinal side effects push a large share of patients to stop within a year. O'Mara has aimed Neurogastrx directly at that gap. In late 2025 the company reported Phase 2 results showing NG101 significantly reduced nausea and vomiting brought on by semaglutide, including a 67% drop in vomiting incidence and a 70% reduction in patient-reported nausea severity compared with placebo.
That framing - patients not able to stay on a good therapy long enough to feel it work - runs through nearly everything O'Mara says publicly. It is a commercial instinct as much as a clinical one, and it reflects where he comes from. He is not a bench scientist who wandered into management. He is an operator and a dealmaker who spent more than two decades in and around gastrointestinal medicine before taking the top job.
The LINZESS years
O'Mara's reputation was built at Ironwood Pharmaceuticals, where he was one of the original members of the team behind LINZESS, a widely prescribed therapy for irritable bowel syndrome. He spent more than ten years there in gastrointestinal drug development and commercialization, helping shape the drug's early commercial profile and then running the deals that carried it abroad.
Those deals were not small. O'Mara directed transaction strategy, sourcing, diligence and negotiations that produced licensing agreements across the United States, Europe, Japan and China. He left Ironwood as Senior Vice President of Corporate Development - a title that captures the shape of his expertise. He knows how a gut drug is designed, how it is priced, and how it gets sold from one continent to the next.
The path there was unusual. O'Mara holds a B.S. in Pharmacy from the Massachusetts College of Pharmacy, then moved into finance rather than the dispensing counter. He started his biotech career at MPM Capital as a Vice President working on business development transactions for emerging companies, and later served as Vice President of Corporate Development at Cozint Interactive, one of the first online market-intelligence firms. The pharmacy training gave him fluency in the science; the venture and corporate-development work taught him how value actually moves in the industry.
Getting the band back together
When O'Mara took the reins at Neurogastrx, he did something telling. Rather than assemble a team of strangers, he brought back people he had already gone to war with. The management group he built around the company's pipeline drew heavily on former Ironwood colleagues - a group that had already brought a GI drug from lab to pharmacy shelf together. In 2021 he closed a $60 million Series B and expanded that leadership bench in the same breath, part of roughly $125 million raised over the company's life.
It is a quiet kind of confidence. Reassembling a proven team says O'Mara trusts execution over novelty, and that he would rather bet on people whose habits he already knows than gamble on a bigger name. For a company that runs lean - Neurogastrx operates with a small core headquarters and outsources much of its development - that trust is not sentimental. It is operational insurance.
What NG101 actually does
NG101 is an orally administered dopamine D2 receptor antagonist. The mechanism is aimed at a small region of the brainstem called the area postrema, a nausea-and-vomiting trigger zone that sits outside the blood-brain barrier. By acting there, the drug is designed to blunt the signals that make patients feel sick without broadly sedating them. Neurogastrx has studied the candidate both in gastroparesis, a condition of delayed stomach emptying, and in the newer, larger opportunity of GLP-1-associated side effects.
The GLP-1 angle is what has drawn the most attention. The market for those medicines has been valued in the tens of billions of dollars, and the persistence problem - only a minority of patients still on treatment after a year - is a well-documented weakness. A drug that meaningfully improves tolerability would not compete with GLP-1s. It would help sell them. That is exactly the kind of complementary, deal-friendly positioning a corporate-development veteran would gravitate toward.
The through-line
What stands out about O'Mara's career is not a single dramatic pivot but the absence of one. He picked a corner of medicine early - the gut - and never really left it. From LINZESS at Ironwood to NG101 at Neurogastrx, the subject matter is remarkably consistent. In an industry that prizes reinvention and platform stories, his edge is depth. He has watched how patients, prescribers and payers behave in this specific area for the better part of a career, and he is deploying that pattern recognition rather than chasing a trend.
The bet now is whether NG101 can move from encouraging mid-stage data into late-stage development and, eventually, to market. O'Mara has said the company looks forward to discussions with the FDA about a larger study. For a leader who has spent his life on the commercial and strategic side of gut medicine, it is the closest he has come to owning the whole story - the science, the deal, and the outcome.